Windtree Therapeutics

Windtree Therapeutics EBIT Margin

The EBIT Margin (Operating Margin) of Windtree Therapeutics (WINT) as of Oct 18, 2026 is -13,626.26 %. In the previous year, EBIT Margin (Operating Margin) was -1,070.41 % — a change of 1,172.99% (lower).

EBIT Margin

-13,626.26 %

YoY

1,172.99%

Last updated:

EBIT Margin (Operating Margin) of Windtree Therapeutics is 2019 -13,626.26 % . EBIT Margin (Operating Margin) of Windtree Therapeutics was 2018 -1,070.41 % . It decreases by 1,172.99% lower compared to the previous year.

For Windtree Therapeutics, the operating (EBIT) margin of -13,626.3% is down versus -4,035.9% a few years ago.

The Windtree Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2012
-193.94 USD
Jan 1, 2013
-114.71 USD
Jan 1, 2014
-1,525.86 USD
Jan 1, 2015
-4,035.87 USD
Jan 1, 2016
-1,811.46 USD
Jan 1, 2017
-1,518.38 USD
Jan 1, 2018
-1,070.41 USD
Jan 1, 2019
-13,626.26 USD
The Windtree Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-13,626.26 %+1,172.99%
-1,070.41 %-29.50%
-1,518.38 %-16.18%
-1,811.46 %-55.12%
-4,035.87 %+164.50%
-1,525.86 %+1,230.17%
-114.71 %-40.85%
-193.94 %+360.49%
-42.12 %+404.60%
-8.35 %-98.11%
-442.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Windtree Therapeutics Stock analysis

What does Windtree Therapeutics do? Windtree Therapeutics Inc., based in Warrington, Pennsylvania, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures KL4 surfactant therapies for respiratory diseases, focusing on respiratory distress syndrome in premature infants. Its core product, AEROSURF (lucinactant for inhalation), targets non-invasive treatment of respiratory conditions. Windtree employs 14 full-time staff and is listed on the stock market since 1995. Windtree Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Windtree Therapeutics stock

EBIT Margin (Operating Margin) of Windtree Therapeutics is -13,626.26 % in 2019.

EBIT Margin (Operating Margin) of Windtree Therapeutics changed from -1,070.41 % to -13,626.26 %, representing a 1,172.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Windtree Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Windtree Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Windtree Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Windtree Therapeutics